<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04070469</url>
  </required_header>
  <id_info>
    <org_study_id>RBHP 2019 VIDAL (MAX-AMOX)</org_study_id>
    <secondary_id>2019-002824-34</secondary_id>
    <nct_id>NCT04070469</nct_id>
  </id_info>
  <brief_title>Plasma Concentrations of Amoxicillin Administered in High-doses During the First Week of Treatment (MAX-AMOX)</brief_title>
  <acronym>MAX-AMOX</acronym>
  <official_title>Plasma Concentrations of Amoxicillin Administered in High-doses During the First Week of Treatment : Intra- and Inter-individual Variability, Factors Associated With Overdose and Adverse Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amoxicillin is the most prescribed antibiotic in France. High dose intravenous amoxicillin,
      (dosage greater than or equal to 150 mg / kg / day or 12 g per day for patients over 80 kg)
      is used in the treatment, in particular, of infectious streptococcal endocarditis. oral,
      streptococci gallolyticus and enterococci, infections of the central nervous system with
      sensitive germs including Streptococcus pneumoniae and Listeria monocytogenes, osteo
      articular infections. The dose-related adverse effects of this antibiotic are nephrological
      (crystalluria may lead to acute renal failure) and neurologic. Recently, the number of
      amoxicillin crystalluria reported to pharmacovigilance centers has increased, having led the
      National Agency of drug and health products safety (ANSM) to recommend the determination of
      the residual level of amoxicillin during the first week of treatment of these patients.
      Nevertheless, there is no precise therapeutic target in patients treated with high dose
      amoxicillin except in the context of critical care. The authors suggest the interest of a
      target between 4 and 10 times the minimum inhibitory concentration (MIC) based on in vitro
      efficacy studies, and retrospective observations of toxicity cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be followed for 8 days. After inclusion, (day of the introduction of high-dose
      amoxicillin treatment), the residual amoxicillin plasma concentrations will be determined at
      Day1, Day4 +/- 1 day and Day7 +/- 1 day of the start of treatment. A urine collection will be
      performed the same day to search for crystalluria and measure the pH and urinary density.

      In case of KDIGO (Kidney Disease Improving Global Outcomes) 2 or 3 stage renal failure or
      neurological signs compatible with overdose, residual amoxicillin and crystalluria and
      urinary density and urinary pH will be measured during the day of discovery of renal failure.

      In the case of KDIGO stage 1 kidney failure, a residual level of amoxicillin and a
      crystalluria search and the measurement of urinary density and urinary pH will be carried out
      the following day, when serum creatinine is checked according to usual practices.

      At day 7 the clinical and infectious biological evolution of the patient will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Residual plasma concentrations of administered in high doses amoxicillin</measure>
    <time_frame>Day 7</time_frame>
    <description>research of Residual plasma concentrations of amoxicillin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Residual plasma concentrations of administered in high doses amoxicillin</measure>
    <time_frame>Day 4</time_frame>
    <description>research of Residual plasma concentrations of amoxicillin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Residual plasma concentrations of administered in high doses amoxicillin</measure>
    <time_frame>Day 1</time_frame>
    <description>research of Residual plasma concentrations of amoxicillin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>search for cystalluria, description of crystals, and infrared spectropscopy to determine crystals composition</measure>
    <time_frame>Day 7</time_frame>
    <description>research in fresh morning urine sample, examined by microscope then infrared spectroscopy in case of crystalluria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>search for cystalluria, description of crystals, and infrared spectropscopy to determine crystals composition</measure>
    <time_frame>Day 4</time_frame>
    <description>research in fresh morning urine sample, examined by microscope then infrared spectroscopy in case of crystalluria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>search for cystalluria, description of crystals, and infrared spectropscopy to determine crystals composition</measure>
    <time_frame>Day 1</time_frame>
    <description>research in fresh morning urine sample, examined by microscope then infrared spectroscopy in case of crystalluria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of residual plasma concentrations above 10 minimal inhibitory concentration (MIC)</measure>
    <time_frame>day 7</time_frame>
    <description>plasma concentrations on blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of residual plasma concentrations above 10 minimal inhibitory concentration (MIC)</measure>
    <time_frame>day 4</time_frame>
    <description>plasma concentrations on blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of residual plasma concentrations above 10 minimal inhibitory concentration (MIC)</measure>
    <time_frame>day 1</time_frame>
    <description>plasma concentrations on blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>density of urines in g/mL</measure>
    <time_frame>Day 7</time_frame>
    <description>research in fresh morning urine sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH of urines</measure>
    <time_frame>Day 7</time_frame>
    <description>research in fresh morning urine sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>density of urines in g/mL</measure>
    <time_frame>Day 4</time_frame>
    <description>research in fresh morning urine sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH of urines</measure>
    <time_frame>Day 4</time_frame>
    <description>research in fresh morning urine sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>density of urines in g/mL</measure>
    <time_frame>Day 1</time_frame>
    <description>research in fresh morning urine sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH of urines</measure>
    <time_frame>Day 1</time_frame>
    <description>research in fresh morning urine sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>confusional state</measure>
    <time_frame>Day 1</time_frame>
    <description>Glasgow coma scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>confusional state</measure>
    <time_frame>Day 4</time_frame>
    <description>Glasgow coma scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>confusional state</measure>
    <time_frame>Day 7</time_frame>
    <description>Glasgow coma scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>encephalitic signs</measure>
    <time_frame>Day 1</time_frame>
    <description>focal neurological signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>encephalitic signs</measure>
    <time_frame>Day 4</time_frame>
    <description>focal neurological signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>encephalitic signs</measure>
    <time_frame>Day 7</time_frame>
    <description>focal neurological signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>epilepsy</measure>
    <time_frame>Day 1</time_frame>
    <description>abnormal movement disorders, seizures and status epilepticus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>epilepsy</measure>
    <time_frame>Day 4</time_frame>
    <description>abnormal movement disorders, seizures and status epilepticus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>epilepsy</measure>
    <time_frame>Day 7</time_frame>
    <description>abnormal movement disorders, seizures and status epilepticus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>age associated with evolution of amoxicillin plasma concentrations</measure>
    <time_frame>Day 0</time_frame>
    <description>in years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body mass index associated with evolution of amoxicillin plasma concentrations</measure>
    <time_frame>Day 0</time_frame>
    <description>weight in kg and height in meters will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function at treatment initiation associated with evolution of amoxicillin plasma concentrations</measure>
    <time_frame>Day 0</time_frame>
    <description>CKD EPI clearance, based on serum creatinine in µmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function impairment during treatment</measure>
    <time_frame>Day 1</time_frame>
    <description>stage of acute kidney injury (based on KDIGO guidelines using variation of serum creatinine in µmol/L compared with baseline, and measure of urine output)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function impairment during treatment</measure>
    <time_frame>Day 4</time_frame>
    <description>stage of acute kidney injury (based on KDIGO guidelines using variation of serum creatinine in µmol/L compared with baseline, and measure of urine output)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function impairment during treatment</measure>
    <time_frame>Day 7</time_frame>
    <description>stage of acute kidney injury (based on KDIGO guidelines using variation of serum creatinine in µmol/L compared with baseline, and measure of urine output)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>germ involved</measure>
    <time_frame>Day 0</time_frame>
    <description>full name of bacteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MIC of germ</measure>
    <time_frame>Day 0</time_frame>
    <description>MIC in mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>site of infection</measure>
    <time_frame>Day 0</time_frame>
    <description>infected organs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infection, Bacterial</condition>
  <arm_group>
    <arm_group_label>Patient reveiving amoxycillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all patient included in this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>dosage of plasma concentration of amoxicillin</description>
    <arm_group_label>Patient reveiving amoxycillin</arm_group_label>
    <other_name>amoxicillin treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major patient, male or female, who has a bacterial infection requiring high dose
             intravenous amoxicillin antibiotic therapy (greater than or equal to 150 mg / kg / day
             with a maximum of 12 grams per day or 12 grams per day for patients over 80 kg),
             according to ANSM recommendations.

          -  Able to provide informed consent to participate.

          -  Covered by a Social Security scheme.

        Exclusion Criteria:

          -  Pregnant, breastfeeding, or likely to be pregnant women and in the absence of a
             negative pregnancy test (blood HCG beta).

          -  Patients under guardianship, curatorship, deprived of liberties or subject to a
             safeguard of justice.

          -  Septic shock justifying treatment with pressurized amines.

          -  Patient under ventilatory or circulatory support.

          -  Patients on dialysis at Baseline or with a creatinin clearance less than or equal to
             30mL / min

          -  Refusal of participation

          -  Hypersensitivity to the active substance, to penicillins. History of a severe
             immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam (e.g.
             cephalosporin, carbapenem or monobactam)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magali VIDAL</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise LACLAUTRE</last_name>
    <phone>+334.73.751.195</phone>
    <email>drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise LACLAUTRE</last_name>
      <phone>+334.73.751.195</phone>
      <email>drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Magali Vidal</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henri Laurichesse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Lesens</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc André</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Clerfond</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clémence Deville</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Moisset</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Ruivard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Soubrier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand Souweine</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amoxycillin</keyword>
  <keyword>drug kinetics</keyword>
  <keyword>drug toxicity</keyword>
  <keyword>crystalluria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

